Molika Ashford covers personalized medicine and molecular diagnostics for GenomeWeb.
The firm's has expanded its ctDNA sequencing test to cover 17 genes, enough to provide a readout of microsatellite instability for guiding cancer immunotherapy use.
The company believes it can provide tests to predict patients' responsiveness to specific drugs akin to the molecular diagnostics that have now swelled the oncology space.
CEO Kim Popovits discussed three strategic imperatives for the coming year: increasing penetration in established markets, broadening global access, and continuing to diversify its portfolio.
The firm is moving into a larger facility after its first full year of profitability and planning new hires to support its plans to bring liquid biopsy kits through the FDA.
The firm has struggled in the past to convince payors of its test's clinical utility but remains dedicated to convincing the field that Epi proColon can help patients by closing CRC screening gaps.
A new analysis of the study yielded mixed news for black women, confirming that they suffer worse outcomes, even with the same genetic test results and treatment.
A study of the detection of potential adverse drug events or interactions found that using PGx information led to better prediction of serious issues, despite no significant change overall.
Following recent publications and anticipating the readout from its NILE study next year, the company plans to make the case that its liquid biopsy approach performs as well as tissue tests.
In the I-SPY 2 trial, investigators analyzed whether MammaPrint scores and BluePrint subtypes could help identify patients who would respond better to treatments.
Investigators shared data at an oncology meeting last week, showing that the test has high sensitivity and specificity in a blinded case-control cohort that included early-stage tumors.